NZ335629A - Use of 1,3-propanediol derivatives for preventing or treating graft vessel disease - Google Patents

Use of 1,3-propanediol derivatives for preventing or treating graft vessel disease

Info

Publication number
NZ335629A
NZ335629A NZ335629A NZ33562997A NZ335629A NZ 335629 A NZ335629 A NZ 335629A NZ 335629 A NZ335629 A NZ 335629A NZ 33562997 A NZ33562997 A NZ 33562997A NZ 335629 A NZ335629 A NZ 335629A
Authority
NZ
New Zealand
Prior art keywords
formula
pharmaceutically acceptable
compound
acceptable salt
salt form
Prior art date
Application number
NZ335629A
Other languages
English (en)
Inventor
Sylvain Cottens
Robert Paul Hof
Roland Wenger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ335629A publication Critical patent/NZ335629A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Light Receiving Elements (AREA)
  • Peptides Or Proteins (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ335629A 1996-11-19 1997-11-17 Use of 1,3-propanediol derivatives for preventing or treating graft vessel disease NZ335629A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds
PCT/EP1997/006408 WO1998022100A2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Publications (1)

Publication Number Publication Date
NZ335629A true NZ335629A (en) 2001-09-28

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335629A NZ335629A (en) 1996-11-19 1997-11-17 Use of 1,3-propanediol derivatives for preventing or treating graft vessel disease

Country Status (24)

Country Link
US (3) US6274629B1 (https=)
EP (2) EP0941082B1 (https=)
JP (2) JP4004070B2 (https=)
CN (2) CN1293876C (https=)
AT (2) ATE369846T1 (https=)
AU (1) AU728420B2 (https=)
BR (1) BR9713105A (https=)
CA (1) CA2270952C (https=)
CZ (1) CZ174999A3 (https=)
DE (2) DE69738033T2 (https=)
DK (1) DK1312359T3 (https=)
ES (2) ES2227726T3 (https=)
GB (1) GB9624038D0 (https=)
HU (1) HUP0000343A3 (https=)
ID (1) ID21568A (https=)
IL (1) IL129824A (https=)
NO (1) NO992259L (https=)
NZ (1) NZ335629A (https=)
PL (1) PL190348B1 (https=)
PT (2) PT1312359E (https=)
RU (1) RU2217136C2 (https=)
SI (1) SI1312359T1 (https=)
SK (1) SK284806B6 (https=)
WO (1) WO1998022100A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457478B1 (en) 1998-11-11 2017-07-19 Novartis AG Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
ES2267993T3 (es) * 2001-02-22 2007-03-16 Novartis Ag Uso de agentes de migracion acelerada de linfocitos para la fabricacion de un medicamento para el tratamiento de la funcion retardada del injerto.
CN1507451A (zh) * 2001-04-20 2004-06-23 �±Ȱ·�ķ�ɷ����޹�˾ 可用作前体药物的修饰环孢菌素及其应用
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
CA2521325C (en) 2003-04-08 2010-09-14 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1643983B1 (en) * 2003-06-24 2010-05-05 The University of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
JP2005272453A (ja) 2004-02-24 2005-10-06 Sankyo Co Ltd アミノアルコール化合物
MX2007001236A (es) * 2004-07-30 2007-03-23 Novartis Ag Formulaciones de compuestos de 2-amino-1, 3-propanodiol.
KR101346527B1 (ko) * 2005-12-15 2013-12-31 미쓰비시 타나베 파마 코퍼레이션 아민 화합물 및 그 의약 용도
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
US9815772B2 (en) * 2013-03-05 2017-11-14 Biocon Limited Process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
US20180250235A1 (en) 2015-09-18 2018-09-06 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CA2114015C (en) * 1991-07-25 2002-12-10 Roland A. Newman Recombinant antibodies for human therapy
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ES2230571T3 (es) 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid

Also Published As

Publication number Publication date
DE69738033T2 (de) 2008-04-30
AU5483198A (en) 1998-06-10
DE69738033D1 (de) 2007-09-27
DE69730727D1 (de) 2004-10-21
US20010056124A1 (en) 2001-12-27
PL333463A1 (en) 1999-12-20
EP0941082A2 (en) 1999-09-15
SK65999A3 (en) 1999-12-10
EP1312359B1 (en) 2007-08-15
EP1312359A3 (en) 2004-01-02
CN1237906A (zh) 1999-12-08
EP1312359A2 (en) 2003-05-21
DE69730727T2 (de) 2005-09-22
CN1146411C (zh) 2004-04-21
JP4004070B2 (ja) 2007-11-07
ES2227726T3 (es) 2005-04-01
ID21568A (id) 1999-06-24
ATE369846T1 (de) 2007-09-15
US6274629B1 (en) 2001-08-14
RU2217136C2 (ru) 2003-11-27
PT941082E (pt) 2004-12-31
WO1998022100A3 (en) 1998-06-25
IL129824A0 (en) 2000-02-29
CA2270952C (en) 2007-09-18
IL129824A (en) 2003-07-31
NO992259D0 (no) 1999-05-10
US6486209B2 (en) 2002-11-26
NO992259L (no) 1999-05-10
HK1022639A1 (en) 2000-08-18
HUP0000343A3 (en) 2001-06-28
CA2270952A1 (en) 1998-05-28
PL190348B1 (pl) 2005-11-30
AU728420B2 (en) 2001-01-11
ATE275947T1 (de) 2004-10-15
SI1312359T1 (sl) 2008-08-31
DK1312359T3 (da) 2007-10-08
GB9624038D0 (en) 1997-01-08
JP2001503780A (ja) 2001-03-21
BR9713105A (pt) 2000-04-11
HUP0000343A2 (hu) 2000-12-28
ES2289041T3 (es) 2008-02-01
WO1998022100A2 (en) 1998-05-28
JP2004256554A (ja) 2004-09-16
CN1515253A (zh) 2004-07-28
EP0941082B1 (en) 2004-09-15
PT1312359E (pt) 2007-11-09
CZ174999A3 (cs) 1999-08-11
CN1293876C (zh) 2007-01-10
US20030069315A1 (en) 2003-04-10
SK284806B6 (sk) 2005-11-03

Similar Documents

Publication Publication Date Title
CA2270952C (en) New use for 1,3-propanediol derivatives
EP0893996B1 (en) Use of a rapamycin derivative in vasculopathies and xenotransplantation
US20080015261A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
HK1057469A (en) Use for 1,3-propanediol compounds
HK1022639B (en) New use for 1,3-propanediol derivatives
HK1060855B (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)